The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine

被引:33
作者
Aweeka, Francesca T.
Rosenkranz, Susan L.
Segal, Yoninah
Coombs, Robert W.
Bardeguez, Arlene
Thevanayagam, Lourdes
Lizak, Patricia
Aberg, Judith
Watts, D. Heather
机构
[1] Univ Calif San Francisco, Drug Res Unit, San Francisco, CA 94143 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[4] Univ Med & Dent New Jersey, Newark, NJ USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] NICHD, NIH, Rockville, MD USA
关键词
zidovudine; intracellular triphosphates; female sex; contraceptive therapy; pharmacokinetics;
D O I
10.1097/01.aids.0000244202.18629.36
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Zidovudine remains part of combination antiretroviral therapy. Pharmacological studies rely on quantitation of active triphosphates in peripheral blood mononuclear cells. This study evaluated the impact of female sex and contraceptive therapy on zidovudine plasma and intracellular pharmacokinetics and the impact of contraceptive therapy on HIV viral load. Methods: Serial plasma and intracellular zidovudine pharmacokinetics following oral and intravenous dosing were determined in 18 men and 20 women treated with zidovudine. Women could repeat pharmacokinetics assessment following 2 months oral or injectable contraceptive therapy. Zidovudine plasma and intracellular mono-, di- and triphosphate concentrations were determined by liquid chromatography tandem mass spectrometry. Plasma and cervical viral loads were determined preceding and following 2 months of contraceptive therapy in women. Results: Men exhibited higher area under the concentration versus time curve for intracellular zidovudine and zidovudine-monophosphate following oral and intravenous dosing and higher zidovudine triphosphate following oral dosing. There was no difference between men and women in plasma zidovudine parameters. Furthermore, contraceptive therapy had no effect on zidovudine plasma or intracellular pharmacokinetics or on plasma or cervical HIV-1 RNA levels. Conclusions: Using an optimized pharmacokinetic design, this study indicated men exhibit significantly higher zidovudine-monophosphate and zidovudine-triphosphate exposure following zidovudine oral administration, having implications for drug toxicity and overall tolerance of zidovudine therapy. The lack of an effect of contraceptive therapy on zidovudine pharmacokinetics is surprising in light of previous pharmacokinetic studies for drugs eliminated primarily through glucuronidation. Contraceptive therapy had no effect on plasma or cervical viral load, results consistent with previous findings. (c) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:1833 / 1841
页数:9
相关论文
共 30 条
[1]   Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV infected individuals [J].
Anderson, PL ;
Kakuda, TN ;
Kawle, S ;
Fletcher, CV .
AIDS, 2003, 17 (15) :2159-2168
[2]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[3]   Lactic acidosis in HIV infected patients: a systematic review of published cases [J].
Arenas-Pinto, A ;
Grant, AD ;
Edwards, S ;
Weller, IVD .
SEXUALLY TRANSMITTED INFECTIONS, 2003, 79 (04) :340-344
[4]   ZIDOVUDINE PHOSPHORYLATION IN HIV-INFECTED PATIENTS AND SERONEGATIVE VOLUNTEERS [J].
BARRY, M ;
WILD, M ;
VEAL, G ;
BACK, D ;
BRECKENRIDGE, A ;
FOX, R ;
BEECHING, N ;
NYE, F ;
CAREY, P ;
TIMMINS, D .
AIDS, 1994, 8 (08) :F1-F5
[5]   Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients [J].
Becher, F ;
Landman, R ;
Mboup, S ;
Kane, CNT ;
Canestri, A ;
Liegeois, F ;
Vray, M ;
Prevot, MH ;
Leleu, G ;
Benech, H .
AIDS, 2004, 18 (02) :181-187
[6]   Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells [J].
Becher, F ;
Schlemmer, D ;
Pruvost, A ;
Nevers, MC ;
Goujard, C ;
Jorajuria, S ;
Guerreiro, C ;
Brossette, T ;
Lebeau, L ;
Créminon, C ;
Grassi, J ;
Benech, H .
ANALYTICAL CHEMISTRY, 2002, 74 (16) :4220-4227
[7]   INHIBITION OF MAMMALIAN DNA POLYMERASE-ASSOCIATED 3' TO 5' EXONUCLEASE ACTIVITY BY 5'-MONOPHOSPHATES OF 3'-AZIDO-3'-DEOXYTHYMIDINE AND 3'-AMINO-3'-DEOXYTHYMIDINE [J].
BRIDGES, EG ;
FARAJ, A ;
SOMMADOSSI, JP .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (08) :1571-1576
[8]   CLINICAL PHARMACOKINETICS OF ZIDOVUDINE - AN OVERVIEW OF CURRENT DATA [J].
COLLINS, JM ;
UNADKAT, JD .
CLINICAL PHARMACOKINETICS, 1989, 17 (01) :1-9
[9]   Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: Implications for applying measurements to individual women [J].
Coombs, RW ;
Wright, DJ ;
Reichelderfer, PS ;
Burns, DN ;
Cohn, J ;
Cu-Uvin, S ;
Baron, PA ;
Cohen, MH ;
Landay, AL ;
Lewis, S ;
Kovacs, A .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (09) :1187-1191
[10]   Recent observations on HIV type-1 infection in the genital tract of men and women [J].
Coombs, RW ;
Reichelderfer, PS ;
Landay, AL .
AIDS, 2003, 17 (04) :455-480